|
Sign In to gain access to subscriptions and/or personal tools.
|
Interferon beta-1b and intravenous methylprednisolone promote lesion recovery in multiple sclerosis
N D Richert
Laboratory of Diagnostic Radiology Research, Clincal Center, Bethesda, Maryland, USA, Department of Diagnostic Imaging and Radiology, Children's National Medical Center, Washington, DC, USA
J L Ostuni
Laboratory of Diagnostic Radiology Research, Clincal Center, Bethesda, Maryland, USA
C N Bash
Laboratory of Diagnostic Radiology Research, Clincal Center, Bethesda, Maryland, USA, Department of Radiology, Uniformed Services University of the Health Sciences, Bethesda, Maryland, USA
T P Leist
Neuroimmunology Branch, National Institute of Neurological Disorders and Stroke, NIH, Bethesda, Maryland, USA
H F McFarland
Neuroimmunology Branch, National Institute of Neurological Disorders and Stroke, NIH, Bethesda, Maryland, USA
J A Frank
Laboratory of Diagnostic Radiology Research, Clincal Center, Bethesda, Maryland, USA
Objective: To determine whether lesion evolution in relapsing-remitting multiple sclerosis (RRMS) patients is altered by treatment with interferonß-1b (IFNb-1b) or by intravenous methylprednisolone (IVMP) as measured by magnetization transfer imaging. Methods: Magnetization transfer ratios (MTR) of 225 contrast enhancing lesions (CEL), in four RRMS patients were serially determined for 12 months before and 12-18 months after contrast enhancement in a baseline vs treatment trial with IFNß-1b. During the baseline period, 185 new CEL were identified: 76 were treated with IVMP (1 giday x 5 days) and designated steroid CEL (S-CEL); the remaining 109 were considered baseline lesions (B-CEL). During IFNß-1b treatment, 40 CEL (IFN-CEL) were identified. After image co-registration, regions of interest (ROIs) defining new CEL were transferred to the MTR image set to determine the mean lesion MTR on each monthly exam. The lesion MTR was compared to MTR of normal appearing white matter (NAWM) on the same exam. Results: As early as 12 months prior to enhancement, the MTR of CEL was reduced compared to NAWM (mean 9.43±3.2%; P<0.001). The further reduction in MTR (28%±4.0) at the time of contrast enhancement was not significantly different for B-CEL, S-CEL or IFN-CEL. Following enhancement, lesion recovery for IFN-CEL (P=0.02) and S-CEL (P=0.002) was significantly higher than B-CEL. Conclusion: IFNß-1b and IVMP reduce tissue damage and promote lesion recovery in RRMS patients. The additional benefit of IVMP compared to IFNß-1b may be related to its inhibitory effect on demyelination.
Key Words: multiple sclerosis • intravenous methylprednisolone • MRI • magnetization transfer imaging • interferon beta-1b gadolinium • contrast enhancing lesions
Multiple Sclerosis, Vol. 7, No. 1,
49-58 (2001)
DOI: 10.1177/135245850100700109
 CiteULike  Complore  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter What's this?
This article has been cited by other articles:
|
|
|
|
 
M. Riva, V.N. Ikonomidou, J.J. Ostuni, P. van Gelderen, S. Auh, J.M. Ohayon, F. Tovar-Moll, N.D. Richert, J.H. Duyn, and F. Bagnato
Tissue-Specific Imaging Is a Robust Methodology to Differentiate In Vivo T1 Black Holes with Advanced Multiple Sclerosis-Induced Damage
AJNR Am. J. Neuroradiol.,
August 1, 2009;
30(7):
1394 - 1401.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E Havrdova, R Zivadinov, J Krasensky, M. Dwyer, I Novakova, O Dolezal, V Ticha, L Dusek, E Houzvickova, J. Cox, et al.
Randomized study of interferon beta-1a, low-dose azathioprine, and low-dose corticosteroids in multiple sclerosis
Multiple Sclerosis,
August 1, 2009;
15(8):
965 - 976.
[Abstract]
[PDF]
|
|
|
|
|
|
|
P. S. Giacomini, I. R. Levesque, L. Ribeiro, S. Narayanan, S. J. Francis, G. B. Pike, and D. L. Arnold
Measuring Demyelination and Remyelination in Acute Multiple Sclerosis Lesion Voxels
Arch Neurol,
March 1, 2009;
66(3):
375 - 381.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D Bar-Zohar, F Agosta, D Goldstaub, and M Filippi
Magnetic resonance imaging metrics and their correlation with clinical outcomes in multiple sclerosis: a review of the literature and future perspectives
Multiple Sclerosis,
July 1, 2008;
14(6):
719 - 727.
[Abstract]
[PDF]
|
|
|
|
|
|
|
J. Cohen, P. Calabresi, S. Chakraborty, K. Edwards, T. Eickenhorst, W. Felton III, E. Fisher, R. Fox, A. Goodman, C. Hara-Cleaver, et al.
Avonex Combination Trial in relapsing--remitting MS: rationale, design and baseline data
Multiple Sclerosis,
April 1, 2008;
14(3):
370 - 382.
[Abstract]
[PDF]
|
|
|
|
|
|
|
D. L. Arnold
Evidence for neuroprotection and remyelination using imaging techniques
Neurology,
May 29, 2007;
68(22_suppl_3):
S83 - S90.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. M. Frohman, O. Stuve, E. Havrdova, J. Corboy, A. Achiron, R. Zivadinov, P. S. Sorensen, J. T. Phillips, B. Weinshenker, K. Hawker, et al.
Therapeutic Considerations for Disease Progression in Multiple Sclerosis: Evidence, Experience, and Future Expectations
Arch Neurol,
October 1, 2005;
62(10):
1519 - 1530.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. J Fox, E. Fisher, J. Tkach, J.-C. Lee, J. A Cohen, and R. A Rudick
Brain atrophy and magnetization transfer ratio following methylprednisolone in multiple sclerosis: short-term changes and long-term implications
Multiple Sclerosis,
April 1, 2005;
11(2):
140 - 145.
[Abstract]
[PDF]
|
|
|
|
|
|
|
F. M. Boneschi, M. Rovaris, G. Comi, and M. Filippi
The use of magnetic resonance imaging in multiple sclerosis: lessons learned from clinical trials
Multiple Sclerosis,
August 1, 2004;
10(4):
341 - 347.
[Abstract]
[PDF]
|
|
|
|
|
|
|
M. Inglese, J.H.T.M. van Waesberghe, M. Rovaris, K. Beckmann, F. Barkhof, D. Hahn, L. Kappos, D.H. Miller, C. Polman, C. Pozzilli, et al.
The effect of interferon {beta}-1b on quantities derived from MT MRI in secondary progressive MS
Neurology,
March 11, 2003;
60(5):
853 - 860.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Wolinsky
MRI aspects of secondary progressive multiple sclerosis
Multiple Sclerosis,
September 1, 2002;
8(1_suppl):
85 - 87.
[PDF]
|
|
|
|
|
|
|
J S Wolinsky
MRI aspects of secondary progressive multiple sclerosis
Multiple Sclerosis,
February 1, 2002;
8(1):
85 - 87.
[PDF]
|
|
|
|
|
